OncoTargets and Therapy
About Dovepress

Open access peer-reviewed scientific and medical journals.
Open Access

Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Advocacy

Support Open Access and Dove Press
Reprints

Promotional Article Monitoring - further details
Favored Author Program

Real benefits for authors, including fast-track processing of papers.

OncoTargets and Therapy

Editor in Chief Professor Hans-Joachim Schmoll

New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab
Argirios Moustakas, Teri N Kreisl

CTLA-4 blockade: therapeutic potential in cancer treatments
Ahmad A Tarhini, Fatima Iqbal

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes
Jacqueline S Garcia, Nitin Jain, Lucy A Godley

Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio

Favored Author Program

We offer real benefits to our authors, including fast-track processing of papers.
Award Nominations Open

Nominations are now open for International Journal of Nanomedicine (IJN) Early Career Scientist Award, International Journal of Nanomedicine (IJN) Distinguished Scientist Award
Call For Submissions

Submit Original Research Article, Review, Case Report, or Rapid Communication in OncoTargets and Therapy
About Dovepress

Dove Medical Press Ltd is a privately held company specializing in the publication of Open Access peer-reviewed journals across the broad spectrum